Catalyst Pharmaceuticals, a Florida, US-based biopharmaceutical company focused on developing drugs for rare diseases, has appointed Gary Ingenito as its Chief Medical Officer.
In this new role, Ingenito will oversee all clinical development programmes, medical affairs, regulatory and other related functions.
For more than 25 years, Ingenito has held executive responsibilities for clinical research, regulatory, drug safety, and medical affairs at pharmaceutical companies and contract research organisations. He initially joined Sandoz Pharmaceuticals in the neuroendocrine group and progressed to become Head of Medical Affairs. He spent eight years at Otsuka Pharmaceuticals, overseeing the approval of anti-infective, cardiovascular and central nervous system products.
Ingenito has also held positions at Corning-Besselaar, SFBC International, Angiotech Pharmaceuticals, Biotest Pharmaceuticals, and, most recently, at Boehringer-Ingelheim Pharmaceuticals, where he was Head of Regulatory Affairs North America for biosimilars.
Ingenito said: 'This is an exciting time to be joining Catalyst as its Chief Medical Officer. As Catalyst's first commercial drug, Firdapse, approaches NDA filing, there will be a number of new systems, procedures, and activities that will be integral to a successful NDA review and product launch, and I look forward to contributing to them.'
